CTLA-4-话题@MedSci

#CTLA-4#

43篇内容 | 3031人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1461879, encodeId=ef4d14618e9ab, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=Agenus的PD-1单抗Balstilimab联合CTLA-4单抗Zalifrelimab治疗晚期宫颈癌，获得FDA的快速通道指定, objectType=article, longId=190021, objectId=dadc19002166, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dadc19002166, replyNumber=0, likeNumber=88, createdTime=2020-03-16, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dadc19002166, moduleTitle=Agenus的PD-1单抗Balstilimab联合CTLA-4单抗Zalifrelimab治疗晚期宫颈癌，获得FDA的快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dadc19002166)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461878, encodeId=fa5214618e8a4, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗肝细胞癌，获得FDA的加速批准, objectType=article, longId=189902, objectId=b3c0189902f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3c0189902f2, replyNumber=0, likeNumber=88, createdTime=2020-03-14, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3c0189902f2, moduleTitle=PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗肝细胞癌，获得FDA的加速批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3c0189902f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461877, encodeId=8f4214618e7d0, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=美国FDA批准新一代抗CTLA-4抗体HBM4003治疗癌症的IND, objectType=article, longId=189090, objectId=bc2b1890908d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc2b1890908d, replyNumber=0, likeNumber=78, createdTime=2020-03-03, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc2b1890908d, moduleTitle=美国FDA批准新一代抗CTLA-4抗体HBM4003治疗癌症的IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc2b1890908d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461876, encodeId=14ba14618e603, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=FDA将对PD-1单抗Opdivo联合CTLA-4单抗Yervoy用作非小细胞肺癌的一线治疗，展开优先审查, objectType=article, longId=186455, objectId=16dd186455e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16dd186455e4, replyNumber=0, likeNumber=82, createdTime=2020-01-19, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16dd186455e4, moduleTitle=FDA将对PD-1单抗Opdivo联合CTLA-4单抗Yervoy用作非小细胞肺癌的一线治疗，展开优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16dd186455e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461875, encodeId=059e14618e549, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=针对PD-1和CTLA-4之外的新型免疫检查点抑制剂VISTA，Curis收购抗VISTA抗体并准备将其商业化, objectType=article, longId=185938, objectId=cf49185938ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf49185938ae, replyNumber=0, likeNumber=76, createdTime=2020-01-10, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf49185938ae, moduleTitle=针对PD-1和CTLA-4之外的新型免疫检查点抑制剂VISTA，Curis收购抗VISTA抗体并准备将其商业化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf49185938ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461874, encodeId=270f14618e4a9, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=FDA批准抗CTLA-4抗体ONC-392的IDN, objectType=article, longId=185514, objectId=40ed18551441, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40ed18551441, replyNumber=0, likeNumber=81, createdTime=2020-01-02, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40ed18551441, moduleTitle=FDA批准抗CTLA-4抗体ONC-392的IDN, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40ed18551441)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461873, encodeId=4a1e14618e34a, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=CTLA-4抑制剂临床研究进展分析, objectType=article, longId=182868, objectId=7d0b182868f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d0b182868f1, replyNumber=0, likeNumber=74, createdTime=2019-11-14, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d0b182868f1, moduleTitle=CTLA-4抑制剂临床研究进展分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d0b182868f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461872, encodeId=611f14618e2f7, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=和铂医药宣布启动用于治疗实体瘤的下一代抗CTLA-4抗体的首次临床研究, objectType=article, longId=182436, objectId=14db1824369b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14db1824369b, replyNumber=0, likeNumber=73, createdTime=2019-11-07, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14db1824369b, moduleTitle=和铂医药宣布启动用于治疗实体瘤的下一代抗CTLA-4抗体的首次临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14db1824369b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461871, encodeId=e03f14618e169, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=BMS的PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗非小细胞肺癌中III期临床成功, objectType=article, longId=181829, objectId=2a12181829fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a12181829fb, replyNumber=0, likeNumber=110, createdTime=2019-10-25, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a12181829fb, moduleTitle=BMS的PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗非小细胞肺癌中III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a12181829fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461870, encodeId=3feb14618e0a0, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=Immunicum AB宣布其DC细胞疗法Ilixadencel与CTLA-4免疫检查点抑制剂联合使用的阳性临床前数据, objectType=article, longId=181706, objectId=bec5181e0657, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bec5181e0657, replyNumber=0, likeNumber=79, createdTime=2019-10-23, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bec5181e0657, moduleTitle=Immunicum AB宣布其DC细胞疗法Ilixadencel与CTLA-4免疫检查点抑制剂联合使用的阳性临床前数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bec5181e0657)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461869, encodeId=3f4614618696b, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=Blood：阻断CTLA-4或可成为对阻断PD-1耐受的cHL患者的新治疗方向, objectType=article, longId=181194, objectId=6f421811940c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f421811940c, replyNumber=0, likeNumber=74, createdTime=2019-10-16, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f421811940c, moduleTitle=Blood：阻断CTLA-4或可成为对阻断PD-1耐受的cHL患者的新治疗方向, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f421811940c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461868, encodeId=9104146186801, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=BMS的PD-1单抗联合CTLA-4单抗治疗肝细胞癌的早期临床结果很有前景, objectType=article, longId=167676, objectId=769c16e676a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=769c16e676a7, replyNumber=0, likeNumber=0, createdTime=2019-06-06, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=769c16e676a7, moduleTitle=BMS的PD-1单抗联合CTLA-4单抗治疗肝细胞癌的早期临床结果很有前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=769c16e676a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461867, encodeId=bf14146186e99, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=Journal for ImmunoTherapy of Cancer：CTLA-4及OX40双特异性抗体ATOR-1015的临床前数据, objectType=article, longId=164218, objectId=ac0f164218bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac0f164218bb, replyNumber=0, likeNumber=71, createdTime=2019-04-15, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac0f164218bb, moduleTitle=Journal for ImmunoTherapy of Cancer：CTLA-4及OX40双特异性抗体ATOR-1015的临床前数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac0f164218bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461866, encodeId=f32714618667f, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=英国NICE批准BMS的肾癌免疫治疗组合：PD-1 单抗Opdivo和CTLA-4 单抗Yervoy, objectType=article, longId=163715, objectId=a607163e15bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a607163e15bb, replyNumber=0, likeNumber=108, createdTime=2019-04-07, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a607163e15bb, moduleTitle=英国NICE批准BMS的肾癌免疫治疗组合：PD-1 单抗Opdivo和CTLA-4 单抗Yervoy, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a607163e15bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461865, encodeId=86fa14618659d, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=CLIN CANCER RES：CTLA-4基因多态性与舒尼替尼治疗透明细胞转移性肾癌患者总生存有关, objectType=article, longId=139972, objectId=55fc1399e220, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55fc1399e220, replyNumber=0, likeNumber=104, createdTime=2018-06-06, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55fc1399e220, moduleTitle=CLIN CANCER RES：CTLA-4基因多态性与舒尼替尼治疗透明细胞转移性肾癌患者总生存有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55fc1399e220)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461864, encodeId=255c1461864b3, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=PD-L1/ CTLA-4免疫联合治疗非小细胞肺癌未能获益, objectType=article, longId=136414, objectId=1d661364149a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d661364149a, replyNumber=0, likeNumber=77, createdTime=2018-04-26, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d661364149a, moduleTitle=PD-L1/ CTLA-4免疫联合治疗非小细胞肺癌未能获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d661364149a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461863, encodeId=ba42146186398, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=ANN ONCOL：接受抗CTLA-4和抗PD-1治疗的患者出现免疫相关不良反应后恢复抗PD-1治疗的安全性, objectType=article, longId=128004, objectId=082012800401, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=082012800401, replyNumber=0, likeNumber=87, createdTime=2018-01-29, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=082012800401, moduleTitle=ANN ONCOL：接受抗CTLA-4和抗PD-1治疗的患者出现免疫相关不良反应后恢复抗PD-1治疗的安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=082012800401)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461862, encodeId=bff61461862b3, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=Cell:免疫疗法大牛James Allison全新：PD-1抗体与CTLA-4抗体原来如此不同, objectType=article, longId=108739, objectId=d029108e3926, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d029108e3926, replyNumber=0, likeNumber=66, createdTime=2017-08-16, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d029108e3926, moduleTitle=Cell:免疫疗法大牛James Allison全新：PD-1抗体与CTLA-4抗体原来如此不同, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d029108e3926)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461861, encodeId=e5f61461861eb, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=CLIN CANCER RES：联合阻断KIT及CTLA-4治疗难治性胃肠道间质瘤及其他肉瘤患者, objectType=article, longId=104303, objectId=5d32104303d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d32104303d2, replyNumber=0, likeNumber=80, createdTime=2017-07-03, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d32104303d2, moduleTitle=CLIN CANCER RES：联合阻断KIT及CTLA-4治疗难治性胃肠道间质瘤及其他肉瘤患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d32104303d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461860, encodeId=536b14618604d, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, objectTitle=PDL-1和CTLA-4招募晚期尿路上皮癌患者, objectType=article, longId=102247, objectId=8ed610224e25, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ed610224e25, replyNumber=0, likeNumber=83, createdTime=2017-06-18, rootId=0, userName=hywen7328, userId=07c46457704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ed610224e25, moduleTitle=PDL-1和CTLA-4招募晚期尿路上皮癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ed610224e25)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CTLA-4

2020-05-29

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

Agenus的PD-1单抗Balstilimab联合CTLA-4单抗Zalifrelimab治疗晚期宫颈癌，获得FDA的快速通道指定

2020-03-16

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗肝细胞癌，获得FDA的加速批准

2020-03-14

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

美国FDA批准新一代抗CTLA-4抗体HBM4003治疗癌症的IND

2020-03-03

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

FDA将对PD-1单抗Opdivo联合CTLA-4单抗Yervoy用作非小细胞肺癌的一线治疗，展开优先审查

2020-01-19

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

针对PD-1和CTLA-4之外的新型免疫检查点抑制剂VISTA，Curis收购抗VISTA抗体并准备将其商业化

2020-01-10

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

FDA批准抗CTLA-4抗体ONC-392的IDN

2020-01-02

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

CTLA-4抑制剂临床研究进展分析

2019-11-14

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

和铂医药宣布启动用于治疗实体瘤的下一代抗CTLA-4抗体的首次临床研究

2019-11-07

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

BMS的PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗非小细胞肺癌中III期临床成功

2019-10-25

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

Immunicum AB宣布其DC细胞疗法Ilixadencel与CTLA-4免疫检查点抑制剂联合使用的阳性临床前数据

2019-10-23

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

Blood：阻断CTLA-4或可成为对阻断PD-1耐受的cHL患者的新治疗方向

2019-10-16

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

BMS的PD-1单抗联合CTLA-4单抗治疗肝细胞癌的早期临床结果很有前景

2019-06-06

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

Journal for ImmunoTherapy of Cancer：CTLA-4及OX40双特异性抗体ATOR-1015的临床前数据

2019-04-15

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

英国NICE批准BMS的肾癌免疫治疗组合：PD-1 单抗Opdivo和CTLA-4 单抗Yervoy

2019-04-07

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

CLIN CANCER RES：CTLA-4基因多态性与舒尼替尼治疗透明细胞转移性肾癌患者总生存有关

2018-06-06

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

PD-L1/ CTLA-4免疫联合治疗非小细胞肺癌未能获益

2018-04-26

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

ANN ONCOL：接受抗CTLA-4和抗PD-1治疗的患者出现免疫相关不良反应后恢复抗PD-1治疗的安全性

2018-01-29

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

Cell:免疫疗法大牛James Allison全新：PD-1抗体与CTLA-4抗体原来如此不同

2017-08-16

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

CLIN CANCER RES：联合阻断KIT及CTLA-4治疗难治性胃肠道间质瘤及其他肉瘤患者

2017-07-03

hywen7328 (审核中...)

前往app查看评论内容

#CTLA-4#

PDL-1和CTLA-4招募晚期尿路上皮癌患者

2017-06-18

科室
- - 订阅+
  - 更多科室
工具
服务